|
Anticancer drug
|
Dropped amount (μg)
|
Recovery (μg)
|
Recovery (%)
|
CV (%)
|
|---|
|
CPA
|
2000
|
1947.2 ± 261.5
|
97.4 ± 13.1
|
13.4
|
|
IFM
|
1000
|
1094.6 ± 87.8
|
109.5 ± 8.8
|
8.0
|
|
CBDCA
|
5000
|
4240.5 ± 618.2
|
84.8 ± 12.4
|
14.6
|
|
CDDP
|
100
|
68.2 ± 11.5
|
68.2 ± 11.5
|
16.9
|
|
MTX
|
6000
|
4890.6 ± 413.3
|
81.5 ± 6.9
|
8.5
|
|
5-FU
|
1000
|
873.2 ± 33.4
|
87.3 ± 3.3
|
3.8
|
|
Ara-C
|
1000
|
726.3 ± 117.3
|
72.6 ± 11.7
|
16.1
|
|
GEM
|
300
|
300.4 ± 27.3
|
100.1 ± 9.1
|
9.1
|
|
ADR
|
1000
|
899.4 ± 121.1
|
89.9 ± 12.1
|
13.5
|
|
Epi-ADR
|
1000
|
475.5 ± 40.8
|
47.6 ± 4.1
|
8.6
|
|
PTX
|
200
|
200.0 ± 18.9
|
100.0 ± 9.5
|
9.5
|
|
DTX
|
200
|
171.1 ± 14.9
|
85.5 ± 7.4
|
8.7
|
|
VP-16
|
500
|
308.7 ± 46.8
|
61.7 ± 9.4
|
15.2
|
|
CPT-11
|
1500
|
1213.2 ± 159.5
|
80.9 ± 10.6
|
13.1
|
- Mean ± SD (μg)(n = 4), CV coefficient of variation (%)
